



NANOBODY® FOR ALZHEIMER'S DISEASE FROM THE ALLIANCE WITH BOEHRINGER INGELHEIM MOVES CLOSER TOWARDS PHASE I CLINICAL TRIALS

- Ablynx to receive €1 million milestone payment -

GHENT, Belgium, 25 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration signed between Ablynx and Boehringer and the event triggers a €1 million milestone payment to Ablynx.

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of \$265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

Dr Edwin Moses, CEO and Chairman of Ablynx, commented:

"We are excited that Boehringer Ingelheim has already submitted a CTA for this Nanobody. This development candidate has the potential to be a first-in-class therapy for Alzheimer's disease and demonstrates the power of our Nanobody platform. We look forward to seeing this programme enter the clinic over the coming months."

About Alzheimer's disease

Alzheimer's disease is the most common form of dementia in adults. It is estimated to affect 4.5 million Americans and over 30 million people worldwide with an average course of 8-12 years. It is projected that the disease prevalence will double over the next 20 years. Marketed products address some of the symptoms, but there are currently no treatments available that delay or halt the progression of the disease. Global sales of Alzheimer's disease drugs were approximately \$8 billion in 2010 and are expected to exceed \$14 billion by 2015.

About Ablynx

[Ablynx](#) is a biopharmaceutical company engaged in the discovery and development of [Nanobodies®](#), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over [25 programmes in the pipeline](#) and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major

pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx:

Dr Edwin Moses
Chairman and CEO

t: +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

+32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Marieke Vermeersch

Investor Relations Manager

t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: marieke.vermeersch@ablynx.com

M:Communications:

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

t: +44 207 920 2330

e: ablynx@mcomgroup.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.